ResoTher Pharma  announces today that the company has closed a financing round with local and European private investors, leading to proceeds of 16.5M DKK in combined financing, consisting of the equity contributoin as well as three non-dilutive grants from Barts Charity, UK; Innovation Foundation, Denmark and the EU Horizon2020 SME instrument. The financing will support the further preclinical development of the company´s lead asset, RTP-026, towards phase I clinical trial entry by supporting both CMC development and further pharmacological and IND-enabling toxicological studies.
Comments from ResoTher Pharma´s CEO Lone Veng: “We are very pleased with having received the valuable recognition from two prestigious funding bodies, as well as having won the confidence of several knowledgeable and experienced private investors and we are grateful for the high degree of external validation of our novel technology. We are now eager to put the investment to work on advancing RTP-026 as we believe that the drug has the ability to significantly impact the lives of patients suffering from myocardial infarction”.